

Express Mail Label No.: EV399525424US
Date of Deposit: April 1, 2004



04-05-09

Attorney Docket No.: 26775-501



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Ornberg et al.
SERIAL NUMBER: 10/702,407 EXAMINER: Not Yet Assigned
FILING DATE: November 5, 2003 ART UNIT: 1614
FOR: BIOPOLYMERS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS

MAIL STOP IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (3 pages), in duplicate;
3. Copies of cited references A1-A42, B1-B10 and C1-C39; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26775-501. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Richard Gervase, Reg. No. 46,725
Matthew J. Golden, Reg. No. 35,161
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
The Chrysler Center
666 Third Avenue
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Dated: April 1, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Ornberg et al.
SERIAL NUMBER: 10/702,407 EXAMINER: Not Yet Assigned
FILING DATE: November 5, 2003 ART UNIT: 1614
FOR: BIOPOLYMERS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS

MAIL STOP IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents. Applicants wish to bring to the examiner's attention that included in this Information Disclosure Statement is the United States published application 2003/0232784, which pending application may contain claims to subject matter claimed in the present application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by

Applicants: Ornberg et al.
U.S.S.N.: 10/702,407

35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.


Please charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 26775-501.

Respectfully submitted,



Richard Gervase, Reg. No., 46,725
Matthew J. Golden, Reg. No. 35,161
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
The Chrysler Center
666 Third Avenue
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115

Dated: April 1, 2004



Please type a plus sign (+) in this box ☐

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/702,407
	Filing Date	11/05/03
	First Named Inventor	Ornberg
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	26775-501

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	4,514,589	04/30/85	Aldinger et al.	174	119	August 27, 1982
	A2	4,718,908	01/12/88	Wigginton et al.	623	16	June 4, 1984
	A3	4,775,426	10/04/88	Murley et al.	148	2	April 3, 1986
	A4	5,013,323	05/07/91	Kobayashi et al.	623	16	August 13, 1987
	A5	5,386,012	01/31/95	Strid	530	331	January 12, 1994
	A6	5,397,362	03/14/95	Noda	623	16	September 27, 1993
	A7	5,403,834	04/04/95	Malfroy-Camine et al.	514	185	December 7, 1992
	A8	5,525,621	06/11/96	Burt et al.	514	393	May 20, 1994
	A9	5,610,293	03/11/97	Riley et al.	540	474	May 16, 1995
	A10	5,626,861	05/06/97	Laurencin et al.	424	426	April 1, 1994
	A11	5,626,863	05/06/97	Hubbell et al.	424	426	January 27, 1995
	A12	5,637,578	06/10/97	Riley et al.	514	186	May 16, 1995
	A13	5,665,428	09/09/97	Cha et al.	427	213.3	October 25, 1995
	A14	5,696,109	12/09/97	Malfroy-Camine et al.	514	185	June 7, 1995
	A15	5,711,763	01/27/98	Nonami et al.	623	16	June 30, 1995
	A16	5,749,839	05/12/98	Kovacs	601	153	May 21, 1996
	A17	5,766,618	06/16/98	Laurencin et al.	424	426	March 5, 1997
	A18	5,800,456	09/01/98	Maeda et al.	606	198	June 13, 1997
	A19	5,817,303	10/06/98	Stedronsky et al.	424	78.02	May 5, 1995
	A20	5,824,047	10/20/98	Moreland	623	1	October 11, 1996
	A21	5,827,880	10/27/98	Malfroy-Camine et al.	514	492	January 26, 1995
	A22	5,830,539	11/03/98	Yan et al.	427	551	November 17, 1995
	A23	5,834,509	11/10/98	Malfroy-Camine et al.	514	492	June 7, 1995
	A24	5,836,313	11/17/98	Perez et al.	128	898	April 14, 1995
	A25	5,840,319	11/24/98	Alakhov et al.	424	400	October 15, 1997
	A26	5,851,227	12/22/98	Spehr	607	126	July 30, 1997
	A27	5,861,032	01/19/99	Subramaniam	623	11	January 31, 1996
	A28	5,869,103	02/09/99	Yeh et al.	424	501	April 4, 1997
	A29	5,871,535	02/16/99	Wolff et al.	623	1	April 27, 1995
	A30	5,873,904	02/23/99	Ragheb et al.	623	1	February 24, 1997
	A31	5,874,421	02/23/99	Riley et al.	514	161	June 6, 1995
	A32	5,876,433	03/02/99	Lunn	623	1	May 29, 1996
	A33	5,876,452	03/02/99	Athanasiou et al.	623	16	May 30, 1995

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A34	5,877,263	03/02/99	Patnaik et al.	525	453	November 25, 1996
	A35	5,879,359	03/09/99	Dorigatti et al.	606	152	May 13, 1997
	A36	5,879,697	03/09/99	Ding et al.	424	422	April 30, 1997
	A37	5,885,609	03/23/99	Amiji	424	425	May 23, 1997
	A38	5,889,130	03/30/99	Worley et al.	526	261	July 31, 1997
	A39	5,891,862	04/06/99	Mandeville, III et al	514	54	September 20, 1996
	A40	6,323,218	11/27/01	Bush et al.	514	311	March 11, 1998
	A41	6,506,411	01/14/03	Hunter et al.	424	501	April 19, 1999

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A42	2003/0232784	12/18/03	Benedict	514	54	June 14, 2002

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	CN	1088069	No English Abstract Available	June 22, 1994		X
	B2	EP	0 524 161	Monsanto Co.	January 20, 1993	X	
	B3	EP	0 598 753	Monsanto Co.	June 1, 1994	X	
	B4	EP	0 679 155	Monsanto Co.	November 2, 1995	X	
	B5	WO	93/11800	The Dow Chemical Co.	June 24, 1993	X	
	B6	WO	93/14093	Board of Regents, The University of Texas	July 22, 1993	X	
	B7	WO	95/28968	Monsanto Co. & G.D. Searle & Co.	November 2, 1995	X	
	B8	WO	96/39396	Monsanto Co.	December 12, 1996	X	
	B9	WO	96/40658	Monsanto Co.	December 19, 1996	X	
	B10	WO	98/58636	G.D. Searle & Co.	December 30, 1998	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Alexander et al. (1970). <i>Inorg. Nucl. Chem. Lett.</i> 6 : 445-448.
	C2	Aston et al. (1994). <i>Tetrahedron Lett.</i> 35 : 3687-3690.
	C3	Babior, B. (1997). <i>Brazilian J. Med. Biol. Res.</i> 30 : 141-155.
	C4	Bannister et al. (1987). <i>CRC Critical Reviews in Biochem.</i> 22 : 111-180.
	C5	Black et al. (1994). <i>J. Pharmacol. and Exp. Therapeutics</i> 270 : 1208-1215.
	C6	Borowiec et al. (1997). <i>Thorac. Cardiovasc. Surgeon</i> 45 : 295-301.
	C7	Bradshaw et al. (1989). <i>J. Heterocyclic Chem.</i> 26 : 1431-1435.
	C8	Brady et al. (1979). <i>J. Org. Chem.</i> 44 : 3101-3105.
	C9	Bulkley, G. (1994). <i>The Lancet</i> 344 : 934-936.
	C10	Cremer et al. (1989). <i>J. Heart Transplantation</i> 8 : 330-336.
	C11	Cundiff and Markunas (1961). <i>Anal. Chem.</i> 33 : 1028-1030.
	C12	Ferrari et al. (1989). <i>Pharmacological Res.</i> 21 : 57-65.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C13	Gristina, A. (1994). <i>Clinical Orthopaedics & Related Res.</i> <u>298</u> : 106-118.
	C14	Gryglewski et al. (1986). <i>Nature</i> <u>320</u> : 454-456.
	C15	Hardy et al. (1994). <i>J. Biol. Chem.</i> <u>269</u> : 18535-18540.
	C16	Kaplan et al. (1992). <i>J. Biomedical Mat. Res.</i> <u>26</u> : 1039-1051.
	C17	Kasten et al. (1995). <i>Proc. Soc. Exp. Biol. Med.</i> <u>208</u> : 170-177.
	C18	Kilgore et al. (1994). <i>J. Mol. Cell Cardiol.</i> <u>26</u> : 995-1006.
	C19	Kimura et al. (1981). <i>Biochimica et Biophysica Acta</i> <u>678</u> : 172-179.
	C20	Krakowiak et al. (1990). <i>J. Org. Chem.</i> <u>55</u> : 3364-3368.
	C21	Lin et al. (1994). <i>Int. J. Oral Maxillofac. Surg.</i> <u>23</u> : 428-429.
	C22	Lindoy, L. In <i>The Chemistry of Macrocyclic Ligand Complexes</i> , The Press Syndicate of the University of Cambridge, 1989, pp. 16, 40-42.
	C23	Michelson, A.M., In <i>Handbook of Methods for Oxygen Radical Research</i> , Greenwald, R.A., Ed.; CRC Boca Raton, 1989, pp. 71-75.
	C24	Moore et al. (1997). <i>J. Biomedical Mat. Res.</i> <u>34</u> : 137-147.
	C25	Newton and Jackels (1988). <i>J. Coord. Chem.</i> <u>19</u> : 265-277.
	C26	Park et al. (1991). <i>J. Polymer Sci.</i> <u>20</u> : 1725-1737.
	C27	Richman et al. (1974). <i>J. Am. Chem. Soc.</i> <u>96</u> : 7-9.
	C28	Riley and Weiss (1997). <i>Cat. Tech.</i> <u>1</u> pp. 41-49.
	C29	Riley et al. (1991). <i>Anal. Biochem.</i> <u>196</u> : 344-349.
	C30	Riley et al. (1999). <i>Inorg. Chem.</i> <u>38</u> : 1908-1917.
	C31	Ross et al. (1996). <i>Bio. Sci. Inst.</i> <u>32</u> : 71-79.
	C32	Shanbhag et al. (1992). <i>J. Biomedical Mat. Res.</i> <u>26</u> : 185-195.
	C33	Siggia et al. "Quantitative Organic Analysis Via Functional Groups", 4th Ed., John Wiley & Sons, pp. 169-172.
	C34	Venturini et al. "A Manganese Based Superoxide Dismutase Mimic Protects Feline Myocardium for Necrosis After Ischemia and Reperfusion." In <i>The Biology of Nitric Oxide</i> , Portland Press, London, 1994, 65-69.
	C35	Weiss and Riley (1996). <i>Drugs of the Future</i> <u>21</u> : 383-389.
	C36	Weiss et al. (1991). <i>J. Cell. Biochem. Suppl.</i> <u>15C</u> : 216, Abstract No. CC110.
	C37	Weiss et al. In <i>The Oxygen Paradox</i> , CLEUP University Press, Padova, Italy, 1995, pp. 641-651
	C38	Weiss et al. (1996). <i>J. Biol. Chem.</i> <u>271</u> : 26149-26156.
	C39	Weiss and Riley "Therapeutic Aspects of Manganese (II)-Based Superoxide Dismutase Mimics" In <i>Inorganic Chemistry in Medicine</i> , Farrell, N. Ed., Royal Society of Chemistry, 1999, Ch. 5.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.